Cellect Biotechnology logo

APOP - Cellect Biotechnology News Story

$2.74 0.0  0.4%

Last Trade - 15/01/21

Sector
Healthcare
Size
Micro Cap
Market Cap £4.60m
Enterprise Value £84.6k
Revenue £n/a
Position in Universe 6086th / 6547

BUZZ-Cellect: Soars on positive bone marrow transplant study data

Mon 11th May, 2020 12:20pm
** U.S. shares of Israel-based biotech co  APOP.O  rise
75.53% to $4.16 premarket
    ** Co reports positive data from bone marrow transplant
study
    ** Co's technology platform, ApoGraft, selects stem cells
for safe and efficient cell therapies by retaining most of the
stem cells but neutralizing harmful mature cells         
    ** Co says its pre-clinical study using ApoGraft for bone
marrow transplantation demonstrates robust engraftment - when
transplanted cells grow and make healthy blood cells
    ** There have been no safety or tolerability concerns so far
- co
    ** Data submitted to U.S. FDA during Investigational New
Drug approval process - APOP
    ** Up to last close, shares up 6.77% YTD 

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.